---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-21-025555"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2021-12-23T23:59:59+00:00"
generated_at: "2026-06-27T22:34:53.690671+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Tempest Therapeutics board member Stella Xu resigns effective Jan 5, 2022

## Summary
- Stella Xu notified the Board of her resignation on Dec 20, 2021, effective Jan 5, 2022.
- Resignation was not due to any disagreement with the company on operations, policies, or practices.
- No replacement has been announced as of the filing date.

## SEC filing metadata
- accession: 0001628280-21-025555
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2021-12-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000162828021025555/0001628280-21-025555-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000162828021025555/tpst-20211220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-21-025555
- JSON: https://secwatch.observer/filing/0001628280-21-025555.json
- Plain text: https://secwatch.observer/filing/0001628280-21-025555.txt

## Key facts
- Executive change
  Stella Xu resigned as Director at Tempest Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On December 20, 2021, Stella Xu notified the board of directors (the “Board”) of Tempest Therapeutics, Inc. (the “Company”) of her decision to resign as a member of the Board, effective January 5, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000162828021025555/0001628280-21-025555-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.